Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (231-240 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|October 11, 2017
Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancerDavid Killock
Nature Reviews. Clinical Oncology|September 29, 2019
Paradoxical roles of mutational load as a determinant of anticancer immunityDavid Killock
Nature Reviews. Clinical Oncology|August 23, 2019
Personalized MRD assays and therapy?David Killock
Nature Reviews. Clinical Oncology|February 28, 2019
ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?David Killock
Nature Reviews. Clinical Oncology|February 25, 2021
Pathological correlates and predictive biomarkers for neoadjuvant ICIs in melanomaDavid Killock
Nature Reviews. Clinical Oncology|February 15, 2017
Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapyDavid Killock
Nature Reviews. Clinical Oncology|June 17, 2025
Second-line tarlatamab improves OS in SCLCDavid Killock
Nature Reviews. Clinical Oncology|June 18, 2025
Zanidatamab shows promise as first-line therapy for advanced-stage HER2<sup>+</sup> GEADavid Killock
Nature Reviews. Rheumatology|June 26, 2013
Lupus nephritis: a rituximab-based regimen might enable oral steroid avoidance in lupus nephritisDavid Killock
Nature Reviews. Rheumatology|March 6, 2013
Osteoarthritis: miR-125b--a new target in cartilage destruction?David Killock
Pageof 31

Showing results (231-240 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|October 11, 2017
Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancerDavid Killock
Nature Reviews. Clinical Oncology|September 29, 2019
Paradoxical roles of mutational load as a determinant of anticancer immunityDavid Killock
Nature Reviews. Clinical Oncology|August 23, 2019
Personalized MRD assays and therapy?David Killock
Nature Reviews. Clinical Oncology|February 28, 2019
ARAMIS - is darolutamide set to become the 'third musketeer' of nmCRPC?David Killock
Nature Reviews. Clinical Oncology|February 25, 2021
Pathological correlates and predictive biomarkers for neoadjuvant ICIs in melanomaDavid Killock
Nature Reviews. Clinical Oncology|February 15, 2017
Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapyDavid Killock
Nature Reviews. Clinical Oncology|June 17, 2025
Second-line tarlatamab improves OS in SCLCDavid Killock
Nature Reviews. Clinical Oncology|June 18, 2025
Zanidatamab shows promise as first-line therapy for advanced-stage HER2<sup>+</sup> GEADavid Killock
Nature Reviews. Rheumatology|June 26, 2013
Lupus nephritis: a rituximab-based regimen might enable oral steroid avoidance in lupus nephritisDavid Killock
Nature Reviews. Rheumatology|March 6, 2013
Osteoarthritis: miR-125b--a new target in cartilage destruction?David Killock
Pageof 31